RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival

Pancreas

Volumn 41, Issue 1, 2012, Pages 84-94

  Lee, Candy N ^a   Heidbrink, Jenny L ^a   McKinnon, Katherine ^a   Bushman, Victoria ^a   Olsen, Henrik ^a   Fitzhugh, William ^a   Li, Aiqun ^a   Van Orden, Karen ^a   He, Tao ^a   Ruben, Steven M ^a   Moore, Paul A ^a  

^a Department of Protein Therapeutics ^*  (United States)

Author keywords

C14ORF1, CD46; integrin 6; proteomics; RNAi; tissue factor

Indexed keywords

BETA6 INTEGRIN; CHROMOSOME 14 OPEN READING FRAME 1 PROTEIN; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANTIGENS, CD46; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA CHAINS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THROMBOPLASTIN;

EID: 84655167118     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182236385     Document Type: Article

References (50)

1. Von Wichert G, Seufferlein T, Adler G. Palliative treatment of pancreatic cancer. J Dig Dis. 2008;9(1):1-7. (Pubitemid 351188933)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
3. Bledi Y, Inberg A, Linial M. PROCEED: a proteomic method for analysing plasma membrane proteins in living mammalian cells. Brief Funct Genomics Proteomics. 2003;2(3):254-265.
4. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727-730. (Pubitemid 37361545)
5. Jang JH, Hanash S. Profiling of the cell surface proteome. Proteomics.2003;3(10):1947-1954. (Pubitemid 37305889)
6. Blonder J, Terunuma A, Conrads TP, et al. A proteomic characterization of the plasma membrane of human epidermis by high-throughput mass spectrometry. J Investig Dermatol. 2004;123(4):691-699. (Pubitemid 39281610)
7. Lee SJ, Kim KH, Park JS, et al. Comparative analysis of cell surface proteins in chronic and acute leukemia cell lines. Biochem Biophys Res Commun. 2007;357(3):620-626. (Pubitemid 46653824)
8. Aggarwal S, He T, Fitzhugh W, et al. Immune modulator CD70 as a potential cisplatin resistance predictive marker in ovarian cancer. Gynecol Oncol. 2009;115(3):430-437.
9. Van OrDen KL, Birse CE, He T, et al. Proteomic Analysis of Colorectal Tumor Cells Indeitifies CD133/Prominin-1, a Cancer Stem Cell Marker, as a Monocolonal Antibody Therapeutic Candidate. Los Angeles, CA: AACR; 2007.
10. Bartz S, Jackson AL. How will RNAi facilitate drug development? Sci STKE. 2005;2005(295):pe39.
11. Kurreck J. Expediting target identification and validation through RNAi. Expert Opin Biol Ther. 2004;4(3):427-429.
12. Schlabach MR, Luo J, Solimini NL, et al. Cancer proliferation gene discovery through functional genomics. Science. 2008;319(5863): 620-624.
13. Tan FL, Yin JQ. Application of RNAi to cancer research and therapy. Front Biosci. 2005;10:1946-1960. (Pubitemid 40529046)
14. Luo J, Elledge SJ. Cancer: deconstructing oncogenesis. Nature. 2008;453(7198):995-996.
15. Iwamura T, Hollingsworth MA. Pancreatic tumors. In: Masters JR, Palsson B, eds. Cancer Cell Lines Part I. New York, NY: Springer; 1999:107-122.
16. Sipos B, Moser S, Kalthoff H, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. 2003;442(5):444-452. (Pubitemid 36718311)
17. Ryu B, Jones J, Blades NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62(3):819-826. (Pubitemid 34126959)
18. Veitia RA, Ottolenghi C, Bissery MC, et al. A novel human gene, encoding a potential membrane protein conserved from yeast to man,is strongly expressed in testis and cancer cell lines. Cytogenet Cell Genet. 1999;85(3-4):217-220. (Pubitemid 29387206)
19. Veitia RA, Hurst LD. Accelerated molecular evolution of insect orthologues of ERG28/C14orf1: a link with ecdysteroid metabolism? J Genet. 2001;80(1):17-21.
20. Kim YJ, Zhan P, Feild B, et al. Reproducibility assessment of relative quantitation strategies for LC-MS based proteomics. Anal Chem. 2007;79(15):5651-5658.
21. Bobbitt JM. Periodate oxidation of carbohydrates. Adv Carbohydr Chem. 1956;48(11):1-41.
22. Bayer EA, Ben-Hur H, Wilchek M. Biocytin hydrazideVa selective label for sialic acids, galactose, and other sugars in glycoconjugates using avidin-biotin technology. Anal Biochem. 1988;170(2):271-281.
23. Zhang H, Li XJ, Martin DB, et al. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003;21(6):660-666. (Pubitemid 36638093)
24. Tuzmen S, Kiefer J, Mousses S. Validation of short interfering RNA knockdowns by quantitative real-time PCR. Methods Mol Biol (Clifton, NJ). 2007;353:177-203. (Pubitemid 350183278)
25. Gygi SP, Rist B, Griffin TJ, et al. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J Proteome Res. 2002;1(1):47-54.
26. Kim YJ, Feild B, Fitzhugh W, et al. Reference map for liquid chromatographyYmass spectrometryYbased quantitative proteomics. Anal Biochem. 2009;393(2):155-162.
27. Forster Y, Meye A, Albrecht S, et al. Tissue factor and tumor: clinical and laboratory aspects. Clin Chim Acta. 2006;364(1-2):12-21. (Pubitemid 43120625)
28. Kim DD, Song WC. Membrane complement regulatory proteins. Clin Immunol (Orlando, Fla). 2006;118(2-3):127-136. (Pubitemid 43199649)
29. Casasnovas JM, Larvie M, Stehle T. Crystal structure of two CD46 domains reveals an extended measles virus-binding surface. EMBO J. 1999;18(11):2911- 2922.
30. Avolio TM, Lee Y, Feng N, et al. RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo. Anticancer Drugs. 2007;18(4):377-388.
31. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1(4):304-313.
32. Gronborg M, Kristiansen TZ, Iwahori A, et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 2006;5(1):157-171. (Pubitemid 43169348)
33. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 2005;129(5):1454-1463.
34. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology. 2005;129(4):1187-1197. (Pubitemid 41446859)
35. Lu Z, Hu L, Evers S, et al. Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics. 2004;4(12):3975-3988. (Pubitemid 39657472)
36. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007;13(10):2870-2875. (Pubitemid 46849560)
37. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2005;11(7):2531-2539.
38. Niehans GA, Cherwitz DL, Staley NA, et al. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol. 1996;149(1):129-142.
39. Weichenthal M, Siemann U, Neuber K, et al. Expression of complement regulator proteins in primary and metastatic malignant melanoma. J Cutan Pathol. 1999;26(5):217-221.
40. Inoue T, Yamakawa M, Takahashi T. Expression of complement regulating factors in gastric cancer cells. Mol Pathol. 2002;55(3):193-199. (Pubitemid 34620770)
41. Hazelbag S, Kenter GG, Gorter A, et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J Pathol. 2007;212(3):316-324. (Pubitemid 47010065)
42. Ahmed N, Riley C, Rice GE, et al. Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer. J Histochem Cytochem. 2002;50(10):1371-1380.
43. Breuss JM, Gallo J, DeLisser HM, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108(pt 6):2241-2251.
44. Jewkes AJ, Macdonald F, Downing R, et al. Labelled antibody imaging in pancreatic cancer, cholangiocarcinoma, chronic pancreatitis and sclerosing cholangitis. Eur J Surg Oncol. 1991;17(4):354-357.
45. Duraker N, Hot S, Polat Y, et al. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95(2):142-147. (Pubitemid 46238983)
46. Goggins M. Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol. 2007;34(4):303-310.
47. Farrell JJ, Van Rijnsoever M, Elsaleh H. Early detection markers in pancreas cancer. Cancer Biomarkers. 2005;1(2-3):157-175.
48. Agrez M, Chen A, Cone RI, et al. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. J Cell Biol. 1994;127(2):547-556.
49. Russell SM, Johnstone RW, Wilton A, et al. Molecular characterization of the polymorphic expression of CD46: β cell surface molecule protecting cells from complement attack. Transplant Proc. 1992;24(1):211-213.
50. Blok VT, Daha MR, Tijsma OM, et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Lab Invest. 2000;80(3):335-344. (Pubitemid 30167793)